Dupilumab and omalizumab are both effective adjuvant treatments for adults with bullous pemphigoid, though dupilumab may provide better outcomes.

COVID-19 infection increases the risk for autoimmune blistering diseases (AIBDs), specifically pemphigus and bullous pemphigoid, according to a study that also found that vaccination against COVID ...

Pemphigus vulgaris is an autoimmune disorder ... not the International Pemphigus and Bullous Pemphigoid Foundation. When we learn of a mistake, we acknowledge it with a correction.

Beyond simple aging, one must consider autoimmune bullous dermatoses (bullous pemphigoid), drug-related causes, metabolic disorders (can occur at any age), cutaneous T-cell lymphomas, scabies ...

Rapid itch reduction was positively correlated with treatment response among patients taking dupilumab for bullous pemphigoid, according to a study. To elucidate the clinical features ...

11, 2024 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that a Dupixent ® (dupilumab) pivotal trial (ADEPT) in bullous pemphigoid (BP) met the ...